Incyte Corporation (INCY) Presents at UBS Global Biopharma Conference 2026 TranscriptSeeking Alpha • Tuesday
Incyte Corporation (INCY) Presents at Jefferies Global Healthcare Conference 2026 TranscriptSeeking Alpha • Tuesday
Povofortay® (povorcitinib) Approved in Europe as the First Once-Daily Oral Treatment for Adults with Moderate to Severe Hidradenitis SuppurativaBusiness Wire • Monday
Incyte Maps Post-Jakafi Growth, Targeting Up to $4 Billion in Other Sales by 2030MarketBeat • 11/11/26
Incyte Corporation (INCY) Presents at 8th Annual Wolfe Research Healthcare Conference TranscriptSeeking Alpha • 11/10/26
Natera Announces Clinical Collaboration with Incyte on Interventional Phase II Study in Colorectal CancerBusiness Wire • 11/10/26
2026 Incyte Ingenuity Awards in GVHD™ Awarded to University of Maryland School of Medicine and H. Lee Moffitt Cancer Center & Research InstituteBusiness Wire • 11/06/26
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 2026Business Wire • 11/04/26
Buy, Sell, or Hold? Today's Top Upgrades and Downgrades: Boston Scientific, DoorDash, GE Vernova, Honeywell Aerospace, Incyte.24/7 Wall Street • 10/30/26
INCY Q3 Loss Narrower Than Expected, Sales Beat, FY'26 View RaisedZacks Investment Research • 10/29/26
Incyte Reports Third Quarter 2026 Financial Results and Provides Business UpdatesBusiness Wire • 10/29/26
Incyte Corporation (INCY) Discusses Solid Tumor Development Strategy and GI Oncology Programs TranscriptSeeking Alpha • 10/27/26
Incyte & Genmab Collaborate to Develop a New Colorectal Cancer TherapyZacks Investment Research • 10/26/26
Incyte Highlights New Data Advancing its Gastrointestinal Cancer Portfolio at ESMO 2026Business Wire • 10/26/26
Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal CancerBusiness Wire • 10/24/26